A real-world study of iruplinalkib in patients with locally advanced or metastatic ALK-positive non-small-cell lung cancer

Status

Active, not recruiting

Phases

Phase 4

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR2400087055

Enrollment

Unknown

Registered

2024-07-18

Start date

2024-08-01

Completion date

Unknown

Last updated

2024-07-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Lung cancer

Interventions

Case series :iruplinalkib

Eligibility

Sex/Gender

All

Age

18 Years to 85 Years

Inclusion criteria

Inclusion criteria: 1. Patients voluntarily used their medical data for this study; 2. ALK positive patients with locally advanced or metastatic non-small-cell lung cancer (NSCLC). 3. Age =18 years old; 4. Has received the the treatment of patients.

Exclusion criteria

Exclusion criteria: 1. Known during pregnancy or lactation women; 2. Patients with congenital long QT syndrome; 3. The researchers think doesn't fit into the group of patients after evaluation.

Design outcomes

Primary

Measure	Time frame
Safety;	—

Secondary

Measure	Time frame
Time to treatment failure events;One-year PFS rate;Objective Response Rate;	—

Countries

China

Contacts

Public ContactRenhua Guo

Jiangsu Provincial Hospital

rhguo@njmu.edu.cn+86 135 8514 5540

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026